{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"5"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"4"},{"groupId":"OG022","value":"10"},{"groupId":"OG023","value":"5"},{"groupId":"OG024","value":"4"},{"groupId":"OG025","value":"4"},{"groupId":"OG026","value":"13"},{"groupId":"OG027","value":"10"},{"groupId":"OG028","value":"13"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"4"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"3"},{"groupId":"OG022","value":"5"},{"groupId":"OG023","value":"5"},{"groupId":"OG024","value":"4"},{"groupId":"OG025","value":"4"},{"groupId":"OG026","value":"11"},{"groupId":"OG027","value":"8"},{"groupId":"OG028","value":"8"}]}],"title":"Treatment-related TEAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"5"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"4"},{"groupId":"OG022","value":"10"},{"groupId":"OG023","value":"5"},{"groupId":"OG024","value":"4"},{"groupId":"OG025","value":"4"},{"groupId":"OG026","value":"13"},{"groupId":"OG027","value":"10"},{"groupId":"OG028","value":"13"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a clinical trial participant.\n\nA TEAE was an AE that started on or after the first dose of investigational product (AMG 176) up to 30 days after the end of investigational product. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were reported as TEAEs.\n\nA treatment-related AE was any TEAE that per investigator review had a reasonable possibility of being caused by the investigational product (AMG 176).","groups":[{"description":"Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG000","title":"Part 1A Cohort 1 (MM): AMG 176 Dose A BIW"},{"description":"Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG001","title":"Part 1A Cohort 2 (MM): AMG 176 Dose B BIW"},{"description":"Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG002","title":"Part 1A Cohort 3 (MM): AMG 176 Dose C BIW"},{"description":"Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG003","title":"Part 1A Cohort 4 (MM): AMG 176 Dose D BIW"},{"description":"Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG004","title":"Part 1A Cohort 5 (MM): AMG 176 Dose E BIW"},{"description":"Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG005","title":"Part 1A Cohort 6 (MM): AMG 176 Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG006","title":"Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG007","title":"Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG008","title":"Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG009","title":"Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG010","title":"Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG011","title":"Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG012","title":"Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG013","title":"Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW"},{"description":"Participants with AML received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG014","title":"Part 3A Cohort 1 (AML): AMG 176 Dose D BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG015","title":"Part 3A Cohort 2 (AML): AMG 176 Dose E BIW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG016","title":"Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW"},{"description":"Japanese participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG017","title":"Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG018","title":"Part 3B Cohort 1 (AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG019","title":"Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG020","title":"Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW"},{"description":"Japanese participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG021","title":"Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 200 mg itraconazole QD for 7 days in week 1.","id":"OG022","title":"Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG023","title":"Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG024","title":"Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG025","title":"Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG026","title":"Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG027","title":"Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG028","title":"Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS included all participants that received at least 1 dose of AMG 176.","reportingStatus":"POSTED","timeFrame":"Day 1 cycle 1 to 30 days after the last dose of AMG 176; median treatment duration was 1.2 months","title":"Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}